Bavarian Nordic (OTCMKTS:BVNRY) Shares Cross Above 50 Day Moving Average - Here's What Happened

Key Points

• Shares crossed above their 50‑day moving average on Thursday, trading as high as $10.41, above the 50‑day ($9.94) and slightly above the 200‑day ($10.37) moving averages on volume of 3,111 shares.
• Key fundamentals: market capitalization roughly $2.47 billion, P/E of 11.83; last quarter EPS was ($0.20) on revenue of $226.16 million, while sell‑side analysts forecast ~0.67 EPS for the current year.
• Bavarian Nordic is a fully integrated biotech specializing in vaccines and immunotherapies, with approved commercial products including Jynneos (Imvamune/Imvanex), Rabipur, and Encepur.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $9.94 and traded as high as $10.41. Bavarian Nordic shares last traded at $10.41, with a volume of 3,111 shares.

Bavarian Nordic Price Performance

The stock's fifty day simple moving average is $9.94 and its two-hundred day simple moving average is $10.37. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 11.83 and a beta of 1.27.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 11.27% and a net margin of 22.20%.The business had revenue of $226.16 million during the quarter. On average, sell-side analysts predict that Bavarian Nordic will post 0.67 EPS for the current year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.